Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells

Oncology Reports
Lorenzo AllegriGiuseppe Damante

Abstract

Anaplastic thyroid carcinoma (ATC) is an extremely aggressive human malignancy characterized by a marked degree of invasiveness, absense of features of thyroid differentiation and resistance to current medical treatment. It is well known that ATCs are characterized by deregulation of genes related to cell cycle regulation, i.e., cyclin-dependent kinases (CDKs) and endogenous cyclin-dependent kinase inhibitors (CDKIs). Therefore, in the present study, the effect of a novel exogenous cyclin-dependent kinase inhibitor, BP-14, was investigated in three human ATC cell lines. The ATC-derived cell lines FRO, SW1736 and 8505C were treated with BP-14 alone or in combination with the mTOR inhibitor everolimus. In all ATC cell lines, treatment with BP-14 decreased cell viability and, in two of them, BP-14 modified expression of genes involved in epithelial-mesenchymal transition. Thus, our data indicate that BP-14 is a potential new compound effective against ATC. Combined treatment with BP-14 and the mTOR inhibitor everolimus had a strong synergistic effect on cell viability in all three cell lines, suggesting that the combined used of CDK and mTOR inhibitors may be a useful strategy for ATC treatment.

References

Nov 9, 2004·Current Opinion in Cell Biology·Adrian M Senderowicz
Jul 21, 2006·Advances in Enzyme Regulation·James A McCubreyMassimo Libra
Feb 23, 2007·Nature Clinical Practice. Endocrinology & Metabolism·Martin SchlumbergerJean-Michel Bidart
Jul 20, 2007·Annals of Surgical Oncology·Hwei-Ming WangChin-Yuan Tzen
Mar 6, 2009·Nature Reviews. Cancer·Kornelia Polyak, Robert A Weinberg
Jun 11, 2009·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·C PapewalisM Schott
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HerseyD Schadendorf
Dec 17, 2009·Thyroid : Official Journal of the American Thyroid Association·Tania PilliBellur S Prabhakar
Feb 18, 2011·Journal of Molecular Endocrinology·Diego RussoSebastiano Filetti
Mar 23, 2011·Expert Review of Anticancer Therapy·Stefan L KojicSam M Wiseman
May 3, 2011·Trends in Biochemical Sciences·Michelle C MendozaJohn Blenis
May 26, 2011·World Journal of Clinical Oncology·Francesco PerriCarlo Buonerba
Apr 16, 2013·Oral Oncology·James Paul O'Neill, Ashok R Shaha
May 8, 2013·International Journal of Cancer. Journal International Du Cancer·Feifei LiLili Wang
Jun 6, 2013·Journal of Cancer Epidemiology·Gabriella PellegritiRiccardo Vigneri
Jul 9, 2013·Journal of Medicinal Chemistry·Tomáš GuckýVladimír Kryštof
Aug 14, 2013·Molecular Cancer Therapeutics·Christine HaiderWolfgang Mikulits
Oct 5, 2013·OncoTargets and Therapy·Nerina DenaroMarco C Merlano
Jan 16, 2014·The Journal of Clinical Endocrinology and Metabolism·Jaime Miguel PitaBranca Maria Cavaco

❮ Previous
Next ❯

Citations

Jan 9, 2019·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Federica BaldanJelena Milasin
Oct 11, 2019·Current Opinion in Oncology·Stefania BulottaDiego Russo
Dec 5, 2017·Journal of Cancer Research and Clinical Oncology·Lorenzo AllegriGiuseppe Damante
Oct 26, 2018·Molecular Cancer·Shikha SainiBellur S Prabhakar
Aug 8, 2021·International Journal of Molecular Sciences·Lorenzo AllegriFederica Baldan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.